January Top 10: Keryx

Before you go, we thought you'd like these...
Before you go close icon

In the following video, Motley Fool health-care analyst David Williamson continues his look at the top-performing health-care stocks of this past January, by highlighting the biggest winner of the month, Keryx . The stock exploded this month, shooting up 247%, although David reminds us that this was possible only because of the stock's starting point after the share price collapsed last year, when a cancer drug it shared with Aeterna Zentaris failed its phase 3 trial. David tells us about the new drug in Keryx's pipeline that is crushing its trial endpoints, and how the new drug compares with its competition.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


The article January Top 10: Keryx originally appeared on Fool.com.

David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners